Annual Report

Overview

The report presents Dainippon Sumitomo Pharma's financial and sustainability performance for the fiscal year ended March 31, 2011. Key business developments include the U.S. market launch of the global strategic product LATUDA® for schizophrenia, entering a European commercialization partnership with Takeda, and expanding overseas revenue. Financially, consolidated net sales reached ¥379.5 billion. The report also details environmental, health, safety, and corporate social responsibility activities, including disaster recovery support for the Great East Japan Earthquake and progress on the Mid-term Environmental Plan.

Document

Report type: Annual Report with Sustainability Disclosures
Class: Embedded
Scope: Full report
Fiscal year: 2010-2011
Period: 1 April 2010 – 31 March 2011
Language: English
Pages
File size

Materiality

Assessment
Basis

Assurance

Statement included

Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services